Trial Profile
Combination of Disitamab Vedotin and Anlotinib in the Treatment of HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer: A Single-Arm, Multicenter, Phase II Clinical Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Disitamab vedotin (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- 24 Oct 2023 Status changed from not yet recruiting to recruiting, as per results presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Results (n=76) assessing efficacy and safety of RC48-ADC in patients with locally advanced or metastatic breast cancer, presented at the 48th European Society for Medical Oncology Congress.
- 23 Aug 2023 New trial record